Second Sight Medical Products (NASDAQ: EYES) is one of 19 publicly-traded companies in the “Medical Devices & Implants” industry, but how does it contrast to its rivals? We will compare Second Sight Medical Products to related businesses based on the strength of its analyst recommendations, dividends, institutional ownership, earnings, profitability, valuation and risk.
Valuation and Earnings
This table compares Second Sight Medical Products and its rivals top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Second Sight Medical Products||$3.98 million||-$33.17 million||-2.99|
|Second Sight Medical Products Competitors||$1.67 billion||$207.58 million||66.60|
This is a summary of recent ratings and price targets for Second Sight Medical Products and its rivals, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Second Sight Medical Products||0||0||1||0||3.00|
|Second Sight Medical Products Competitors||113||734||1030||10||2.50|
Second Sight Medical Products currently has a consensus target price of $5.00, suggesting a potential upside of 150.00%. As a group, “Medical Devices & Implants” companies have a potential upside of 38.59%. Given Second Sight Medical Products’ stronger consensus rating and higher possible upside, equities research analysts clearly believe Second Sight Medical Products is more favorable than its rivals.
This table compares Second Sight Medical Products and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Second Sight Medical Products||-565.12%||-184.87%||-137.77%|
|Second Sight Medical Products Competitors||-101.23%||-92.70%||-30.32%|
Volatility & Risk
Second Sight Medical Products has a beta of 3.67, indicating that its share price is 267% more volatile than the S&P 500. Comparatively, Second Sight Medical Products’ rivals have a beta of 0.21, indicating that their average share price is 79% less volatile than the S&P 500.
Insider & Institutional Ownership
12.7% of Second Sight Medical Products shares are owned by institutional investors. Comparatively, 54.4% of shares of all “Medical Devices & Implants” companies are owned by institutional investors. 50.9% of Second Sight Medical Products shares are owned by insiders. Comparatively, 11.9% of shares of all “Medical Devices & Implants” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Second Sight Medical Products rivals beat Second Sight Medical Products on 8 of the 13 factors compared.
About Second Sight Medical Products
Second Sight Medical Products, Inc. is engaged in developing, manufacturing and marketing prosthetic devices that restore vision to blind individuals. The Company’s product, the Argus II System, treats outer retinal degenerations, such as retinitis pigmentosa (RP). The Argus II System provides an artificial form of vision that differs from the vision of people with normal sight. It does not restore normal vision and it does not slow or reverse the progression of the disease. The Company’s Argus II System employs electrical stimulation to bypass degenerated photoreceptor cells and to stimulate remaining viable retinal cells thereby inducing visual perception in blind individuals. The Argus II System works by converting video images captured by a miniature camera housed in a patient’s glasses into a series of small electrical pulses that are transmitted wirelessly to an array of electrodes that are implanted on the surface of the retina.
What are top analysts saying about Second Sight Medical Products? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Second Sight Medical Products and related companies.